



HAL
open science

Microbial biotransformation of furosemide for environmental risk assessment: identification of metabolites and toxicological evaluation

Hugo Olvera-Vargas, Sébastien Leroy, Michael Rivard, Nihal Oturan, Mehmet Oturan, Didier Buisson

► **To cite this version:**

Hugo Olvera-Vargas, Sébastien Leroy, Michael Rivard, Nihal Oturan, Mehmet Oturan, et al.. Microbial biotransformation of furosemide for environmental risk assessment: identification of metabolites and toxicological evaluation. *Environmental Science and Pollution Research*, 2016, 23 (22), pp.22691-22700. 10.1007/s11356-016-7398-2. hal-02115198

HAL Id: hal-02115198

<https://hal.science/hal-02115198>

Submitted on 30 Mar 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1
2 **Microbial biotransformation of furosemide for environmental risk**
3 **assessment: identification of metabolites and toxicological evaluation**
4

5 Hugo Olvera-Vargas ^{a,b}, Sébastien Leroy ^a Michael Rivard ^c, Nihal Oturan ^b,
6 Mehmet Oturan ^b and Didier Buisson ^{a*}
7
8

9 ^aUnité Molécules de Communication et Adaptation des Micro-organismes (MCAM, UMR
10 7245) Sorbonne Universités, Muséum national d'Histoire naturelle, CNRS, CP 54, 57 Rue
11 Cuvier, 75005 Paris Cedex 05, France.
12

13 ^bUniversité Paris-Est, Laboratoire Géomatériaux et Environnement (LGE), EA 4508, UPEM,
14 77454 Marne-la-Vallée, France.

15
16 ^c Université Paris-Est, Institut de Chimie et des Matériaux de Paris-Est, UMR CNRS UPEC
17 7182, 94320 Thiais, France
18

19
20
21 * Corresponding authors: Didier Buisson

22 E-mail buisson@mnhn.fr

23 Tel: 33 (0)1 40 79 81 24

24 Fax: 33 (0)1 40 79 31 35
25
26

1 **Abstract:**

2
3 Some widely prescribed drugs are sparsely metabolized, and end up in the environment. They can thus be a focal
4 point of ecotoxicity, either themselves or their environmental transformation products. In this context, we
5 present a study concerning furosemide, a diuretic, which is mainly excreted unchanged. We investigated its
6 biotransformation by two environmental fungi, *Aspergillus candidus* and *Cunninghamella echinulata*. The
7 assessment of its ecotoxicity and that of its metabolites was performed using the Microtox test (ISO 11348-3)
8 with *Vibrio fischeri* marine bacteria. Three metabolites were identified by means of HPLC-MS and ¹H/¹³C NMR
9 analysis: saluamine, a known pyridinium derivative and a hydroxy-ketone product, the latter having not been
10 previously described. This hydroxy-ketone metabolite was obtained with *C. echinulata* and was further slowly
11 transformed into saluamine. The pyridinium derivative was obtained in low amount with both strains.
12 Metabolites, excepting saluamine, exhibited higher toxicity than furosemide, being the pyridinium structure the
13 one with the most elevated toxic levels (EC₅₀=34.40±6.84 mg L⁻¹). These results demonstrate that biotic
14 environmental transformation products may present a higher environmental risk than the starting drug, hence
15 highlighting the importance of boosting toxicological risk assessment related to the impact of pharmaceutical
16 waste.

17
18 **Keywords:**

19 Biodegradation, oxidation, degradation pathway, environmental transformation products, ecotoxicology

20
21

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

Introduction

Pharmaceuticals, which are substances designed to possess biological effects, are able to affect any function of the body of man or animals and they are used in diagnosis, prevention or cure of diseases. They are produced and used in large tonnage, and their presence in the environment as hazardous contaminants is now well recognized (Agerstrand et al. 2015; Khetan and Collins 2007). Several reports have shown their presence in effluents of sewage treatment plants (STPs) (Loos et al. 2013). Indeed, most pharmaceuticals enter municipal STPs via domestic and hospital sewages or through industrial discharges, part of them escaping degradation (Al Aukidy et al. 2014; Frederic and Yves 2014). They have been unequivocally detected in surface, ground and in some cases, even in drinking water. Despite their low concentrations levels, their continuous release into the environment, makes them pseudo-persistent and hence a focal point of toxicity risk (Fent et al. 2006).

Once in the environment, pharmaceuticals undergo conversion processes that can induce the formation of a great variety of transformation products (TPs). They can be metabolized by different microorganisms (biotic transformations) and/or undergo photolysis, hydrolysis or chemical oxidation (abiotic transformations). In like manner, drugs can be transformed during sewage and drinking water treatment, resulting in the generation of different biologically and chemically transformed products (Fatta-Kassinos et al. 2011). These TPs may have similar activity to the parent compound, or may be biologically more active and/or more toxic (Dirany et al. 2011; Khetan and Collins 2007; Morais et al. 2014). Additionally, they are commonly present as complex mixtures, whose combined toxicity may exceed that of each isolated compounds (Backhaus and Karlsson 2014). Consequently, the presence of pharmaceuticals and their TPs in environmental water sources represent a substantial toxicological risk for living organisms and humans (Celiz et al. 2009; de Jesus Gaffney et al. 2015). Determining the toxicity and ecotoxicity of these persistent micropollutants and their TPs is thus fundamental and a prerequisite for thorough risk assessment aiming at a comprehensive protection of the environment.

Microorganisms possess multiple-enzyme systems allowing them to metabolize xenobiotics into a wide range of transformation products. Accordingly, several active microbial strains, especially fungi, have been used as a competitive and ecologically effective approach for the preparation of diverse metabolites for different purposes, including drug metabolism studies (Azerad 1999; Marvalin and Azerad 2011). *Aspergillus* species have been widely used for the preparation of several potentially bioactive derivatives, whence evidencing its ability to biotransform a variety of chemicals (Adelin et al. 2011; Arakawa et al. 2013; Parshikov et al. 2015). Similarly, *Cunninghamella* species, a filamentous fungus found in soil and plant material, particularly at Mediterranean and subtropical zones, are able to perform biotransformations using both, phase I (oxidative) and phase II (conjugative) bio-mechanisms, imitating mammalian metabolism. In fact, they have P450 monooxygenase systems comparable to those in mammals and enzymes conducting phase II metabolism of drugs (Asha and Vidyavathi 2009; Felczak et al. 2016). In this way, microbial metabolism of xenobiotics is widely used as a model for mammalian metabolism studies. Paradoxically, the use of isolated wild strains in the investigation of the fate of drugs in the environment is not widespread (Murphy 2016), in spite of the potentiality of biotransformations as a very useful tool for the preparation of drugs' transformation metabolites, aiming to strengthen and support predictive modelling and analysis on ecotoxicity and risk assessment.

Furosemide (FRSM), a widely prescribed loop diuretic, has been unambiguously detected in aquatic environments (Besse and Garric 2008; Mendoza et al. 2015; Oliveira et al. 2015) and it has been classified by

1 the European Medicine Agency as one of the highest risk pharmaceuticals based on its exposure criteria
2 (Huschek et al. 2004). It has been reported to cause side effects on some species, mainly hepatotoxicity and
3 ototoxicity. Furthermore, its carcinogenic and genotoxic potential has also been suggested (Bucher et al. 1990;
4 Mondal et al. 2012). These toxicological effects have been associated with the formation of toxic metabolites,
5 which are capable of disrupting cellular functions by binding relevant cell macromolecules. A metabolite, under
6 the form of an electrophilic epoxide, has been reported to be highly cytotoxic to liver hepatocytes (Williams et
7 al. 2007). Moreover, FRSM alone or in mixture with other pharmaceuticals was reported to show estrogenic
8 activity, mixtures having synergistic effects (Fent et al. 2006). Recently, we reported the microbial
9 biotransformation of FRSM by selected bacteria and fungi, which were able to metabolize FRSM into saluamine
10 (SLMN), a pyridinium derivative (PRDN) and another product. The pyridinium derivative was reported to be
11 more toxic than the parent drug (Laurencé et al. 2014). Moreover, both metabolites, SLMN and PRDN, were as
12 well detected during electrochemical oxidation of the drug by electro-Fenton (EF) process (Olvera-Vargas et al.
13 2015), whence suggesting their high probability to be generated as environmental transformation products.

14 The significant progress on the ongoing regulation concerning pharmaceutical residues witnesses the
15 increasing preoccupation about this environmental problem. In fact, three pharmaceuticals have been included in
16 the “watch list” of emerging pollutants within the European Water Framework Directive (Directive 2013/39/EU)
17 (Kuster and Adler 2014; Ribeiro et al. 2015). However, data related to toxicological effects of medicines and
18 their TPs in the environment is still scarce and sometimes ambiguous, thereby, it is of primordial importance to
19 reinforce environmental risk assessment through ecotoxicological approaches aiming at stablishing the most
20 appropriate strategies for environmental management and monitoring regarding pharmaceutical waste. The
21 present work investigates the bioconversion of FRSM by the environmental fungi *Aspergillus candidus* and
22 *Cunninghamella echinulate* for toxicological evaluation. Three main metabolites were formed: SLMN, PRDN
23 derivative, and a hydroxy-ketone (HK), the latter being described for the first time. A mechanistic pathway for
24 the metabolism of FRSM by *Cunninghamella echinulata* is proposed and ecotoxicological assays using *V.*
25 *fischeri* bacteria revealed that PRDN and HK metabolites possess higher toxicological levels than FRSM itself.

26 **Materials and Methods**

27 **Chemicals and analysis methods**

28
29
30
31 Furosemide (purity > 98%), trifluoroacetic acid and formic acid were of reagent grade from Fluka. PRDN was
32 synthesized as described (Laurencé et al. 2011). Gradient grade HiPersolv acetonitrile from VWR was used.

33 HPLC analysis was performed on Gilson system (pump 305, pump 306, gradient dynamic mixer 811B
34 and autoinjector 234) with a Supelcosil LC-18, 3µm (75 mm × 4.6 mm) column. The system was controlled and
35 the results were analyzed by Unipoint Gilson software. Column was eluted with an appropriate solvent system at
36 a flow of 1.0 mL/min: (solvent A: water, 0.1% trifluoroacetic acid; solvent B: 50% water/ 50% acetonitrile, 0.1%
37 trifluoroacetic acid) 0-5 min (isocratic 90/10), 5-8 min (gradient up to 50/50), 8-15 min (gradient up to 20/80),
38 15-20 min (isocratic 20/80). The detection was at 240 nm using an UV detector.

39 LC-MS analyses were performed on Nexera UHPLC chromatographer coupled with a MS2020 simple
40 quadrupole mass spectrometer from Shimadzu, using atmospheric pressure chemical ionization (APCI). 1 µL of
41 sample solutions were injected through a Nexera autosampler. A Kinetex column, 2.7µm, C18 100 Å, 100 x 2.1
42 mm, from Phenomenex, was used, and a 10 min program was developed for these analyses using a binary A/B

1 solvent system at a flow rate of 0.5 mL/min (solvent A: methanol, 0.01% formic acid; solvent B: water, 0.01%
2 formic acid): 0-2 min (isocratic 5/95), 2-7 min (gradient up to 80/20), 7-8 min (isocratic 80/20). Eluted
3 compounds were detected between m/z 50 and 600. Optimal MS settings were fixed as follows: Drying gas:
4 nitrogen, 15 L min⁻¹; nebulizing gas: nitrogen, 1.5 L min⁻¹; Qarray RF: 60 V; Qarray DC: 0 V; DL voltage and
5 temperature: 0 V and 250 °C; Detector voltage: 1.1 kV; APCI interface voltage: +4.5 kV; Event time: 200 ms.

6 Preparative HPLC was performed on an Agilent system, using an Agilent PrepHT XDB-C18 column
7 (21.2 x 150 mm; 5 µm; USA). Sample was injected and separated using the same gradient program for HPLC
8 analysis. 3 main peaks were obtained and collected in separated fractions.

9 Mass spectra data were recorded using an electrospray time of flight mass spectrometer (ESI-TOF-MS)
10 operating in positive and negative modes (QSTAR Pulsar I of Applied Biosystems). NMR experiments were
11 recorded on Bruker Avance III HD 400 MHz spectrometers (Wissembourg, France) equipped with a BBFO Plus
12 Smartprobe.

14 Microorganisms and culture conditions

16 Fungal strains were obtained from the American Type Culture Collection (*Cunninghamella echinulata*
17 ATCC 9245, and *Aspergillus candidus* ATCC 20023). Cultures were maintained on agar slants (containing in
18 g L⁻¹: bacto-peptones 5, yeast extract 5, malt extract 5, glucose 20 and agar 20) and stored at 4 °C. Liquid culture
19 media containing (g L⁻¹) glucose 16, yeast extract 4, malt extract 10 and soybean peptones 5 (YMS medium)
20 were sterilized without glucose at 120 °C for 20 min. Separately sterilized glucose solution (40%) was added
21 afterwards. Flasks (100 mL) containing 50 mL of YMS culture medium were inoculated with glycerol
22 suspension of microorganisms and incubated at 30 °C and 200 rpm (orbital shaker) for 60 h.

24 Biotransformations

26 For time-course studies of biotransformation, biomass was filtered, suspended in citrate or phosphate
27 buffer and substrate was added in DMF solution for a final concentration of 0.4 g L⁻¹. Biotransformations were
28 performed in light. Samples were taken at regular intervals of time: 200 µL of methanol were added to 800 µL of
29 biomass-containing sample, which was further stirred, sonicated and centrifuged prior to injection. A control
30 experiment without biomass addition was conducted under the same conditions. No decrease in the
31 concentration of FRSM was observed after 24 h, showing that photolysis of the drug is not significant.

33 Production of hydroxy-ketone and saluamine

35 *C. echinulata* ATCC 9245 was cultured in YMS medium (2 L) as describe above. Biomass (300 g) was
36 harvested by filtration and suspended in citrate buffer (0.5 L, 0.1 M pH 5). Furosemide was added (200 mg) in
37 DMF solution, final concentration 0.4 g L⁻¹. Incubation was performed under an air atmosphere at 27 °C and 200
38 rpm for 72 h. Cells suspension was filtered and incubation medium was extracted with ethyl acetate (3 times).
39 Crude extract was re-dissolved in methanol and purified by preparative HPLC, giving SLMN (64 mg) in 42%
40 yield and HK (34 mg) in 17% yield.

1 HK: HRMS (ESI-TOF) M-H⁺: *m/z* calc mass for C₁₂H₁₄ClNO₆S 349.0261 g mol⁻¹, found 349.0141 g mol⁻¹. ¹H
2 NMR (400 MHz, DMSO-*d*₆) δ (ppm): 8.69 (t, J=4.8 Hz, 1H, N-H), 8.38 (s, 1H, H-10), 6.82 (s, 1H, H-7), 4.3 (d,
3 J=4.8, 2H, H-5), 3.39 (t, j=6.4 Hz, 2H, H-3), 2.53 (t, J=7.3Hz, 2H, H-2), 1.68 (m, 2H, H-1). ¹³C NMR
4 (100 MHz, DMSO-*d*₆) δ (ppm): 206.04 (C-4), 168.8 (C-12), 152.4 (C-6), 136.7 (C-8), 133.7 (C-10), 127.1 (C-
5 9), 114.4 (C-7), 108.4 (C-11), 60.5 (C-1), 52.4 (C-5), 36.7 (C-3), 27.03 (C-2).

6

7 Ecotoxicological tests

8

9 Toxicity tests were conducted with the photo-luminescent bacteria *V. fischeri*. The bioassay measures the
10 decrease in bioluminescence induced in the cell metabolism by the presence of chemicals and it was performed
11 in accordance with ISO 11348-3 procedure (Microtox[®]). The bacteria and the activation reagent, LCK 487
12 LUMISTOX, were provided by Hach Lange France SAS. A dilution series of the standard solutions of
13 furosemide and the isolated metabolites: pyrimidium derivative, saluamine and hydroxyl-ketone, were prepared
14 in 2% NaCl and pH was adjusted to a value of 7. Bioluminescence intensity was measured using a luminometer
15 Berthold[™] Autolumat Plus LB 953, at time zero and after 15 min of exposure to the samples at 15 °C and
16 compared to the measured value of the control solution (NaCl 2%). Concentration of the toxicants produces a
17 dose-response relationship from which the results as the 50% and 20% inhibition effective concentration (EC20
18 and EC50, respectively) were deduced by non-linear regression curves with variable Hill slope. Reported
19 toxicity values are the average of 3 replicates of each sample with 95% confidence limits. Phenol was tested as a
20 control and it was found to be within the Microtox[®] set parameters, EC50 between 13 and 26 mg L⁻¹.

21

22 **Results**

23

24 *Identification of furosemide metabolites*

25

26 Biotransformation of FRSM by *C. echinulata* was conducted in preparative scale during 72 h. The
27 chromatograms obtained by HPLC analysis showed the presence of 2 peaks apart from that of FRSM (Fig. 1A).
28 The corresponding products were purified by preparative chromatography and analyzed by LC-MS (Fig. 2). The
29 MS spectrum in negative mode of the more polar compound M1 (R_t=4.0 min) showed a molecular ion *m/z* 249,
30 corresponding to the [M-H⁻] ion (Fig. 2 B and D). Along with the ¹H NMR analysis, where protons from the
31 furan ring were not observed, this product was identified as SLMN, whose formation by this fungus was
32 confirmed.




Figure 1. HPLC chromatograms of biotransformation of FRSM by *C. echinulata* ATCC 9245 (A) and by *A. candidus* ATCC 20023 (B).

The MS spectrum in negative mode of the second compound M2 (Rt=5.01 min) showed a molecular ion $[M-H]^-$ at m/z 349 (Fig. 2 C and E) corresponding to an increase of 20 u compared to furosemide, which resulted from the addition of one oxygen and four hydrogen atoms. The presence of the chlorine atom in this metabolite was confirmed by the fact that the MS spectrum showed three peaks at m/z 349.0141, 351.0120 and 353.018 with relative intensity of 100, 30 and 10 respectively (Fig. S1). Additionally, the interpretation of the 1H NMR and ^{13}C NMR spectra (Fig. S2 and S3), along with the two dimensional COSY, HSQS and HMBC spectra, allowed the unambiguous identification of the HK product with a molecular mass of $350.77 \text{ g mol}^{-1}$. The MS/MS daughter ion spectrum (negative ion) showed a fragment at m/z 305 (loss of 44 u, CO_2), confirming the presence of the alkyl group. A fragmentation ion at m/z 227 (loss of $35 + 87$ u), indicated the loss of chlorine and the $-COCH_2CH_2CH_2OH$ group, which corresponded to cleavage next to the keto group. Moreover, the MS spectrum in negative mode of the HK solubilized in methanol, revealed a protonated molecular ion m/z 363.0105 (Fig. S4), which corresponds to the ketal adduct resulting from intramolecular cyclization and addition of one molecule of methanol.

Regarding the biotransformation of FRSM by *A. candidus*, the chromatograms obtained in HPLC analysis during incubation also showed the presence of two peaks apart from that of FRSM (Fig. 1B), one of them having the same retention time of SLMN. The presence of the latter was confirmed by LC-MS analysis since an m/z peak of 249 in negative mode was observed (Fig. 3 C and E). Compound M3 showed a Rt of 1.2 min and an m/z peak of 329 in positive mode in LC-MS, which corresponded to PRDN (Fig. 3 B and C). Its formation was confirmed by the HRMS spectrum of the brut extract, which showed a peak at m/z 328.9975.




Figure 2. Biotransformation of furosemide by *C. echinulata* ATCC 9245. LC-MS ion-current chromatogram (negative ion current) of m/z 329 (A), of m/z 249 (B) and of m/z 349 (C) and masse spectra of peaks at R_t = 4 min (D) and at R_t = 5 min (E)





Figure 3. Biotransformation of furosemide by *A. candidus* ATCC 20023. LC-MS ion-current chromatogram of m/z 329 in negative mode (A), of m/z 329 in positive mode (B) and of m/z 249 in negative mode (C) and masse spectra of peaks at R_t = 6 min (D) and at R_t = 1.1 min (E)

Effect of incubation conditions

The time courses of the bioconversion of FRSM were investigated in two different buffers, 0.1 M citrate buffer pH 5 and 0.1 M phosphate buffer pH 7. The results were illustrated in Figs. 4 and 5 for representative biotransformation. Fig. 4 shows the evolution of FRSM and its metabolites SLMN and HK in terms of the


1 percentage of peak area, assuming that all metabolites have a similar molar absorption coefficient. The evolution
 2 of PRDN, which was formed in much lesser amounts, is given in Fig. 5. It can be seen from Fig. 4A that FRSM
 3 was almost completely metabolized by *C. echinulata* when incubation was performed in phosphate buffer, while
 4 during incubations with *A. candidus* (Fig. 4B), only 50% of FRSM was converted into SLMN as the main
 5 product. HK was the main metabolite produced by *C. echinulata*, however, its disappearance was observed after
 6 a long incubation time, as it was progressively transformed into SLMN. This fact was verified by incubation of
 7 purified HK with *C. echinulata*, which resulted in the formation of SLMN (Fig. S5). A control experiment was
 8 carried out in the absence of biomass, in which no significant decay on the concentration of HK was perceived,
 9 hence confirming that HK was not altered by abiotic factors. Moreover, an increase in the pH of the solution
 10 was observed during biotransformation (Figs. 4 and 5), especially for the incubations carried out in citrate buffer.
 11 In all cases, pH reached a value of 8 after 168 hours of incubation, which can be attributed to the progressive
 12 metabolism of citrate by the microorganism. It may be noted that this increase of pH coincided with the
 13 appearance of SLMN.



14
 15 **Figure 4.** Evolution of FRSM and its metabolites during biotransformation of the drug by *C. echinulata* ATCC
 16 9245 (A and B) and *A. candidus* ATCC 20023 (C and D) in different buffers: citrate pH 5 (A and C), phosphate
 17 pH 7 (B and D). FRSM (■), HK (▲), SLMN (◆), pH buffer citrate (---▷---), pH buffer phosphate (---○---).
 18

19
 20 Concerning PRDN (Fig. 5), this metabolite was produced by both microorganisms in all conditions, but
 21 in greater amount when using *A. candidus*. It is noteworthy that for both strains, PRDN appeared until the
 22 medium reached a pH value of 6 (Fig. 5) when citrate buffer was utilized (pH 5), thus suggesting that its
 23 formation is pH dependent, also taking into account that it was generated from the first stages of incubation

1 when phosphate buffer (pH 7) was used. Finally, the influence of PRDN on FRSM biotransformation by *A.*
 2 *candidus* was assessed. The addition of PRDN in the incubation medium was found to entail inhibition of FRSM
 3 metabolism; hence formation of SLMN did not take place.




4 **Figure 5.** Evolution of PRDN metabolite during FRSM biotransformation by *C. echunilata* ATCC 9245 (A) and
 5 *A. candidus* ATCC 20023 (B). PRDN buffer citrate (▶), PRDN buffer phosphate (●), pH buffer citrate (--▷--)
 6 and pH buffer phosphate (--○--).
 7
 8


9 *Ecotoxicological assessment*

10
 11 Toxicity evaluation was carried out by means of the *V. fischeri* bioluminescence acute test. Toxicity values are
 12 expressed in terms of the effective concentration (EC₅₀ and EC₂₀), which represents the concentration causing
 13 50% and 20% of inhibition of luminescence, respectively (Fig. 6). These values were determined by fitting the
 14 experimental data to dose-response curves with variable Hill slope. The concentration-response curves are
 15 depicted in Fig. 7. Toxicity of FRSM and HK product are only expressed as EC₂₀ being that they did not provoke
 16 more than 30% and 50% of luminescence inhibition, respectively, at the tested concentrations. Only the data at
 17 15 min contact were considered, as negligible difference was observed between the other exposure times.

18 The most remarkable issue is that metabolites HK and PRDN presented the highest toxicity levels, with
 19 EC₅₀ = 34.40±6.84 mg L⁻¹ and EC₂₀ = 18.94±3.81 mg L⁻¹ for PRDN, and EC₂₀ = 37.42±7.96 mg L⁻¹ for HK.



1
2 **Figure 6.** EC20 (■) and EC50 (■) toxicity values (mg L⁻¹) for *V. fischeri* luminisnece acute tests with
3 95% confidence limits. NE = No Effect.
4



5
6 **Figure 7.** Inhibition percentage curves for FRSM (■) and the prepared metabolites, PRDN (×) and HK (▲),
7 fitted to nonlinear regression with variable Hill slope.
8
9


10 Discussion

11 Biotransformation

12 Three metabolites have been observed during the biotransformations of FRSM, whose identification allowed
13 proposing the metabolic pathway described in scheme 1. SLMN was formed by both microorganisms and it
14 resulted from FRSM *N*-dealkylation, which occurs through hydroxylation in the α -position of the amino group
15 involving monooxygenase like cytochrome P450 enzyme, followed by hydrolysis of the hemiaminal
16 intermediate (Hezari and Davis 1992; Williams et al. 2007). SLMN has also been detected as stable metabolite

1 during the incubation of FRSM in the presence of river sediments (Li et al. 2014). These finding demonstrate
 2 that the use of microorganisms for the synthesis of TPs from pharmaceuticals is a potential approach for
 3 assessing the fate of drugs in environmental organisms.

4 HK, formed by *C. echinulata*, resulted from the oxidation of the furan ring. Such oxidation reactions
 5 involving cytochromes P450 have been reported through the formation of a *cis*-enedicarbonyl intermediate. Two
 6 mechanisms have been proposed: the formation of an epoxide followed by hydrolysis, or direct formation of *cis*-
 7 enedicarbonyl compound through the addition of the high valent iron (IV)-oxospecies to the π -system of the
 8 furan ring (Guengerich 2003). The double bond and the aldehyde group of the resulting *cis*-enedicarbonyl
 9 compound can be further reduced to form HK (Scheme 1). Indeed, it has been reported that aldehydes can be
 10 either reduced into the corresponding alcohol by microorganisms or oxidized into the corresponding carboxylic
 11 acid in animals (Lacroix et al. 1997). Interestingly, Antoine et al. detected a similar compound as one of the
 12 major biliary metabolites of FRSM in rats, an γ -keto-carboxylic acid derivative (Antoine et al. 2007). This γ -
 13 keto-carboxylic acid compound was also found during the electrochemical degradation of FRSM by means of
 14 the EF process (Olvera-Vargas et al. 2015).



15
 16
 17
 18
Scheme 1. Proposed pathway for biotransformation of furosemide by *C. echinulata* ATCC 9245

1 Regarding PRDN, it was first reported by Chen et al. (Chen and Burka 2007), who explained its
2 formation through intramolecular condensation of the amino group with the aldehyde of the generated *cis*-
3 enediacarbonyl intermediate, this intermediate being common in the formation route of both, HK and PRDN
4 metabolites (scheme 1). In the case of *C. echinulata*, reduction of the aldehyde group resulted to be faster than its
5 condensation with the amino group, hence mostly generating HK. Laurencé et al. (Laurencé et al. 2014) also
6 described the generation of this compound during both, the microbial bioconversion of FRSM and its
7 electrochemical oxidation.

8 The dependency of FRSM's bioconversion on pH is an important fact being as it suggests that
9 environmental conditions play a relevant role on the biodegradation of drugs. It is thus important to take into
10 consideration these factors when assessing ecotoxicological and environmental risk.

11 12 *Ecotoxicological aspects*

13 Ecotoxicity assessment of furosemide and its microbial metabolites was carried out, firstly because furosemide
14 and its metabolites have been described as having toxicological effects towards different organisms (Peterson
15 2013), and secondly because its occurrence in the environment with its concomitant biotic transformation
16 (Jakimska et al. 2014) may degenerate into potential ecotoxic metabolites such as the PRDN derivative.

17 A low toxicity value was found for FRSM, $EC_{20} = 72.29 \text{ mg L}^{-1}$, evidencing its limited acute toxicity on
18 *V. fischeri*. This result slightly differs from that found by Isidori et al. (Isidori et al. 2006), who reported no lethal
19 risk for the same marine bacterium, and for the rotifers *Brachionus calyciflorus*. Similarly, a toxicological
20 assessment conducted on this drug employing cnidarian *Hydra vulgaris*, deployed an absent toxicity at
21 concentrations up to 1 mg L^{-1} (Pascoe et al. 2003). Likewise, in a recent study, a moderate environmental risk
22 was reported for FRSM, which was associated principally to its persistence and bioaccumulation, rather than to
23 its toxicity (Mendoza et al. 2015). Nonetheless, these results contrast with the toxicological evaluation conducted
24 on rodents and fish, which demonstrated the elevated hazard represented by this diuretic drug. Furthermore,
25 FRSM was recently reported to present high toxicological risk for invertebrates and moderate risk for fish,
26 according to its Risk Quotient (RQ) (Papageorgiou et al. 2016).

27 On the other hand, results demonstrate that the TPs resulting from the biotransformation of FRSM are
28 more toxic than FRSM itself, a fact that has been previously suggested by some authors as discussed below.

29 PRDN gave the greatest ecotoxicity values, $EC_{50} = 34.40 \pm 6.84 \text{ mg L}^{-1}$. Furthermore, its inhibitory
30 effects on fungal oxidative enzymes were demonstrated since its presence hindered FRSM's metabolism. This
31 detrimental effect could also cause ecotoxicity as formerly described for other drugs (Barra Caracciolo et al.
32 2015). Previous toxicological evaluation reports also revealed PRDN's noxious effects with an $EC_{50} = 973 \pm 46$
33 μM according to the MTT test, as well as induction of cell death by the caspase-3 assay. Moreover, its use to
34 induce symptoms associated to Parkinson's disease for a chemical model of this neurodegenerative disorder has
35 been recently patented (Martens et al. 2014).

36 Regarding HK derivative, which has not hitherto been identified, it exhibited higher ecotoxicity than the
37 parent drug ($EC_{20} = 36.60 \text{ mg L}^{-1}$), however being less toxic than PRDN. HK is a reactive intermediate resulting
38 from the oxidation of FRSM's furan ring, whose progressive enzymatic oxidation was found to yield SLMN.

1 The latter didn't show any effect towards *V. fischeri* bacteria, which is in agreement with a previous toxicity
2 study on SLMN that also evidenced a lack of hazardous effects (Laurencé et al. 2014). These findings suggest
3 that toxicological effects can be attributed mainly to the highly active aromatic moieties; the furan and
4 pyridinium rings.

5 Toxicity values indicate that the formed metabolites have a restricted acute toxicity on bacteria *V.*
6 *fischeri* even at concentration ranges above the environmental levels. Nevertheless, the identification of
7 metabolites having higher adverse effects than the parent drug denotes the necessity of investigating not only
8 parent compounds but also potential TPs when assessing environmental impact, mostly taking into account that
9 these hazardous compounds represent a potential risk for aquatic life by the long-term at low-level exposure,
10 causing more subtle effects in growth, fertility, sex ratios, or reproductive anomalies (Khetan and Collins 2007).
11 Therefore, these findings point out the urgency of intensifying toxicological assessment facing the increasingly
12 worrying ecological and health risk posed by pharmaceutical residues and their TPs.

13

14 **Conclusion**

15 It has been confirmed that the environmental fungi *Cunninghamella echinulata* and *Aspergillus*
16 *candidus* are capable of metabolizing FRSM into 3 main transformation products: saluamine, a pyridinium
17 derivative and a hydroxy-ketone product, the latter having been described for the first time. Toxicity acute essays
18 demonstrated that pyridinium and hydroxy-ketone metabolites have higher toxicity levels towards *V. fischeri*
19 bacteria than FRSM. These results highlight the capacity of different microorganisms to transform
20 pharmaceutical residues into stable metabolites, which are highly probable to be found in environmental water
21 sources, therefore representing an ecotoxicological risk for both, ecosystems and human beings, as some of them
22 can be even more toxic than the departing drug. Accordingly, this integral work gives a general perspective of the
23 fate of drugs and their pernicious effects in the environment, which is essential for assessing environmental risk
24 with the goal of developing the most convenient strategies for environmental management, including water
25 control. Furthermore, this study can be regarded as a tool for the assessment of biotic transformation products
26 from pharmaceutical pollutants, in response to the urgent necessity of reinforcing the evaluation of
27 environmental hazard. Moreover, it contributes with valuable information with respect to the effects of drugs on
28 environmental microbial communities, which is crucial for the comprehension of the biodegradation
29 mechanisms drugs suffer in natural environments, as well as the harmful impacts on microbes.

30

31 **Acknowledgments**

32 The authors wish to thank L. Dubost for mass spectra and A. Deville for NMR spectra.

33

34 **Funding** This study was funded by European Commission through the Erasmus Mundus Joint Doctorate
35 Programme « Environmental Technologies for Contaminated Solids, Soils and Sediments » (grant number FPA
36 n°2010-0009), and CONACyT, Mexico.

37

38 **Conflict of interest** The authors declare that they have no conflict of interest.

39

1 **Ethical approval** This article does not contain any studies with human participants or animals performed by any
2 of the authors.

3 4 5 **References**

- 6
7 Adelin E, Servy C, Cortial S, Levaique H, Gallard JF, Martin MT, Retailleau P, Bussaban B, Lumyong S,
8 Ouazzani J (2011) Biotransformation of natural compounds. Oxido-reduction of Sch-642305 by
9 *Aspergillus ochraceus* ATCC 1009. *Bioorg Med Chem Lett* 21:2456-2459 doi:10.1016/j.bmcl.2011.02.063
- 10 Agerstrand M, Berg C, Bjorlenius B, Breitholtz M, Brunstrom B, Fick J, Gunnarsson L, Larsson DG, Sumpter
11 JP, Tysklind M, Ruden C (2015) Improving environmental risk assessment of human pharmaceuticals.
12 *Environ Sci Technol* 49:5336-5345 doi:10.1021/acs.est.5b00302
- 13 Al Aukidy M, Verlicchi P, Voulvoulis N (2014) A framework for the assessment of the environmental risk
14 posed by pharmaceuticals originating from hospital effluents. *Sci Total Environ* 493:54-64
15 doi:10.1016/j.scitotenv.2014.05.128
- 16 Antoine DJ, Williams DP, Regan SL, Park BK (2007) Formation of cytotoxic protein reactive metabolites from
17 furosemide: Biological consequences of drug metabolism. *Toxicology* 240:157-157 doi:Doi
18 10.1016/J.Tox.2007.06.079
- 19 Arakawa NS, Gobbo-Neto L, Ambrosio SR, Antonucci GA, Sampaio SV, Pupo MT, Said S, Schmidt TJ, Da
20 Costa FB (2013) Unusual biotransformation products of the sesquiterpene lactone budlein A by *Aspergillus*
21 species. *Phytochemistry* 96:92-100 doi:10.1016/j.phytochem.2013.09.022
- 22 Asha S, Vidyavathi M (2009) *Cunninghamella*--a microbial model for drug metabolism studies--a review.
23 *Biotechnol Adv* 27:16-29 doi:10.1016/j.biotechadv.2008.07.005
- 24 Azerad R (1999) Microbial models for drug metabolism. *Advances in Biochemical Engineering/ biotechnology*
25 63:169-218
- 26 Backhaus T, Karlsson M (2014) Screening level mixture risk assessment of pharmaceuticals in STP effluents.
27 *Water Res* 49:157-165 doi:10.1016/j.watres.2013.11.005
- 28 Barra Caracciolo A, Topp E, Grenni P (2015) Pharmaceuticals in the environment: Biodegradation and effects
29 on natural microbial communities. A review. *Journal of Pharmaceutical and Biomedical Analysis* 106:25-
30 36 doi:10.1016/j.jpba.2014.11.040
- 31 Besse JP, Garric J (2008) Human pharmaceuticals in surface waters implementation of a prioritization
32 methodology and application to the French situation. *Toxicol Lett* 176:104-123
33 doi:10.1016/J.Toxlet.2007.10.012
- 34 Bucher JR, Huff J, Haseman JK, Eustis SL, Davis WE, Jr., Meierhenry EF (1990) Toxicology and
35 carcinogenicity studies of diuretics in F344 rats and B6C3F1 mice. 2. Furosemide. *J Appl Toxicol* 10:369-
36 378 doi:10.1002/jat.2550100510
- 37 Celiz MD, Tso J, Aga DS (2009) Pharmaceutical Metabolites in the Environment: Analytical Challenges and
38 Ecological Risks. *Environ Toxicol Chem* 28:2473-2484 doi:10.1897/09-173.1
- 39 Chen LJ, Burka LT (2007) Chemical and enzymatic oxidation of furosemide: formation of pyridinium salts.
40 *Chem Res Toxicol* 20:1741-1744 doi:10.1021/tx700262z
- 41 de Jesus Gaffney V, Almeida CM, Rodrigues A, Ferreira E, Benoliel MJ, Cardoso VV (2015) Occurrence of
42 pharmaceuticals in a water supply system and related human health risk assessment. *Water Res* 72:199-208
43 doi:10.1016/j.watres.2014.10.027
- 44 Dirany A, Efremova Aaron S, Oturan N, Sires I, Oturan MA, Aaron JJ (2011) Study of the toxicity of
45 sulfamethoxazole and its degradation products in water by a bioluminescence method during application of
46 the electro-Fenton treatment. *Anal Bioanal Chem* 400:353-360 doi:10.1007/s00216-010-4441-x
- 47 Fatta-Kassinos D, Vasquez MI, Kummerer K (2011) Transformation products of pharmaceuticals in surface
48 waters and wastewater formed during photolysis and advanced oxidation processes - degradation,
49 elucidation of byproducts and assessment of their biological potency. *Chemosphere* 85:693-709
50 doi:10.1016/j.chemosphere.2011.06.082
- 51 Felczak A, Bernat P, Rozalska S, Lisowska K (2016) Quinoline biodegradation by filamentous fungus
52 *Cunninghamella elegans* and adaptive modifications of the fungal membrane composition. *Environ Sci*
53 *Pollut Res Int* doi:10.1007/s11356-016-6116-4
- 54 Fent K, Weston AA, Caminada D (2006) Ecotoxicology of human pharmaceuticals. *Aquat Toxicol* 76:122-159
55 doi:10.1016/j.aquatox.2005.09.009
- 56 Frederic O, Yves P (2014) Pharmaceuticals in hospital wastewater: Their ecotoxicity and contribution to the
57 environmental hazard of the effluent. *Chemosphere* 115:31-39 doi:10.1016/j.chemosphere.2014.01.016
- 58 Guengerich FP (2003) Cytochrome P450 oxidations in the generation of reactive electrophiles: epoxidation and
59 related reactions. *Arch Biochem Biophys* 409:59-71 doi:10.1016/S0003-9861(02)00415-0

- 1 Hezari M, Davis PJ (1992) Microbial models of mammalian metabolism. N-dealkylation of furosemide to yield
2 the mammalian metabolite CSA using *Cunninghamella elegans*. *Drug Metab Dispos* 20:882-888
- 3 Huschek G, Hansen PD, Maurer HH, Krenzel D, Kayser A, European C (2004) Environmental risk assessment
4 of medicinal products for human use according to European Commission recommendations. *Environ*
5 *Toxicol* 19:226-240 doi:10.1002/tox.20015
- 6 Isidori M, Nardelli A, Parrella A, Pascarella L, Previtiera L (2006) A multispecies study to assess the toxic and
7 genotoxic effect of pharmaceuticals: furosemide and its photoproduct. *Chemosphere* 63:785-793
8 doi:10.1016/j.chemosphere.2005.07.078
- 9 Jakimska A, Sliwka-Kaszynska M, Reszczyńska J, Namiesnik J, Kot-Wasik A (2014) Elucidation of
10 transformation pathway of ketoprofen, ibuprofen, and furosemide in surface water and their occurrence in
11 the aqueous environment using UHPLC-QTOF-MS. *Anal Bioanal Chem* 406:3667-3680
12 doi:10.1007/s00216-014-7614-1
- 13 Khetan SK, Collins TJ (2007) Human pharmaceuticals in the aquatic environment: A challenge to green
14 chemistry. *Chem Rev* 107:2319-2364 doi:10.1021/cr020441w
- 15 Kuster A, Adler N (2014) Pharmaceuticals in the environment: scientific evidence of risks and its regulation.
16 *Philos Trans R Soc Lond B Biol Sci* 369 doi:10.1098/rstb.2013.0587
- 17 Lacroix I, Biton J, Azerad R (1997) Microbial biotransformations of a synthetic immunomodulating agent,
18 HR325. *Bioorg Med Chem* 5:1369-1380 doi:10.1016/S0968-0896(97)00094-1
- 19 Laurencé C, Rivard M, Lachaise I, Bensemhoun J, Martens T (2011) Preparative access to transformation
20 products (TPs) of furosemide: a versatile application of anodic oxidation. *Tetrahedron* 67:9518-9521
21 doi:10.1016/J.Tet.2011.10.006
- 22 Laurencé C, Rivard M, Martens T, Morin C, Buisson D, Bourcier S, Sablier M, Oturan MA (2014) Anticipating
23 the fate and impact of organic environmental contaminants: A new approach applied to the pharmaceutical
24 furosemide. *Chemosphere* 113:193-199 doi:Doi 10.1016/J.Chemosphere.2014.05.036
- 25 Li Z, Maier MP, Radke M (2014) Screening for pharmaceutical transformation products formed in river
26 sediment by combining ultrahigh performance liquid chromatography/high resolution mass spectrometry
27 with a rapid data-processing method. *Anal Chim Acta* 810:61-70 doi:10.1016/j.aca.2013.12.012
- 28 Loos R, Carvalho R, Antonio DC, Comero S, Locoro G, Tavazzi S, Paracchini B, Ghiani M, Lettieri T, Blaha L,
29 Jarosova B, Voorspoels S, Servaes K, Haglund P, Fick J, Lindberg RH, Schwesig D, Gawlik BM (2013)
30 EU-wide monitoring survey on emerging polar organic contaminants in wastewater treatment plant
31 effluents. *Water Res* 47:6475-6487 doi:10.1016/j.watres.2013.08.024
- 32 Martens T, Rivard M, Laurence C, Morin C, Lehri-Boufala S (2014) Chemical model of a neurodegenerative
33 disease, method for preparation and uses of same. *WO* 2014076439,
- 34 Marvalin C, Azerad R (2011) Microbial production of phase I and phase II metabolites of propranolol.
35 *Xenobiotica* 41:175-186 doi:10.3109/00498254.2010.535219
- 36 Mendoza A, Acena J, Perez S, Lopez de Alda M, Barcelo D, Gil A, Valcarcel Y (2015) Pharmaceuticals and
37 iodinated contrast media in a hospital wastewater: A case study to analyse their presence and characterise
38 their environmental risk and hazard. *Environ Res* 140:225-241 doi:10.1016/j.envres.2015.04.003
- 39 Mondal SC, Tripathi DN, Vikram A, Ramarao P, Jena GB (2012) Furosemide-induced genotoxicity and
40 cytotoxicity in the hepatocytes, but weak genotoxicity in the bone marrow cells of mice. *Fundam Clin*
41 *Pharmacol* 26:383-392 doi:10.1111/j.1472-8206.2011.00927.x
- 42 Morais SA, Delerue-Matos C, Gabarrell X (2014) An uncertainty and sensitivity analysis applied to the
43 prioritisation of pharmaceuticals as surface water contaminants from wastewater treatment plant direct
44 emissions. *Sci Total Environ* 490:342-350 doi:10.1016/j.scitotenv.2014.04.082
- 45 Murphy CD (2016) Microbial degradation of fluorinated drugs: biochemical pathways, impacts on the
46 environment and potential applications. *Appl Microbiol Biotechnol* 100:2617-2627 doi:10.1007/s00253-
47 016-7304-3
- 48 Oliveira TS, Murphy M, Mendola N, Wong V, Carlson D, Waring L (2015) Characterization of Pharmaceuticals
49 and Personal Care products in hospital effluent and waste water influent/effluent by direct-injection LC-
50 MS-MS. *Sci Total Environ* 518-519:459-478 doi:10.1016/j.scitotenv.2015.02.104
- 51 Olvera-Vargas H, Oturan N, Buisson D, van Hullebusch ED, Oturan MA (2015) Electro-Oxidation of the
52 Pharmaceutical Furosemide: Kinetics, Mechanism, and By-Products. *CLEAN – Soil, Air, Water* 43:1455-
53 1463 doi:10.1002/clen.201400656
- 54 Papageorgiou M, Kosma C, Lambropoulou D (2016) Seasonal occurrence, removal, mass loading and
55 environmental risk assessment of 55 pharmaceuticals and personal care products in a municipal wastewater
56 treatment plant in Central Greece. *Sci Total Environ* 543:547-569 doi:10.1016/j.scitotenv.2015.11.047
- 57 Parshikov IA, Woodling KA, Sutherland JB (2015) Biotransformations of organic compounds mediated by
58 cultures of *Aspergillus niger*. *Appl Microbiol Biotechnol* 99:6971-6986 doi:10.1007/s00253-015-6765-0
- 59 Pascoe D, Karntanut W, Muller CT (2003) Do pharmaceuticals affect freshwater invertebrates? A study with the
60 cnidarian *Hydra vulgaris*. *Chemosphere* 51:521-528 doi:10.1016/S0045-6535(02)00860-3

1 Peterson LA (2013) Reactive metabolites in the biotransformation of molecules containing a furan ring. *Chem*
2 *Res Toxicol* 26:6-25 doi:10.1021/tx3003824
3 Ribeiro AR, Nunes OC, Pereira MF, Silva AM (2015) An overview on the advanced oxidation processes applied
4 for the treatment of water pollutants defined in the recently launched Directive 2013/39/EU. *Environ Int*
5 75:33-51 doi:10.1016/j.envint.2014.10.027
6 Williams DP, Antoine DJ, Butler PJ, Jones R, Randle L, Payne A, Howard M, Gardner I, Blagg J, Park BK
7 (2007) The metabolism and toxicity of furosemide in the Wistar rat and CD-1 mouse: a chemical and
8 biochemical definition of the toxicophore. *J Pharmacol Exp Ther* 322:1208-1220
9 doi:10.1124/Jpet.107.125302
10
11

Figure captions

- 1
2
3 **Scheme 1.** Proposed pathway for biotransformation of furosemide by *C. echinulata* ATCC 9245
4 **Figure 1.** Representative HPLC chromatograms of FRSM biotransformation by *C. echinulata* ATCC 9245 (A)
5 and by *A. candidus* ATCC 20023 (B).
6 **Figure 2.** Biotransformation of furosemide by *C. echinulata*. LC-MS ion-current chromatogram (negative ion
7 current) of m/z 329 (A), of m/z 249 (B) and of m/z 349 (C) and masse spectra of peak at Rt = 4 min (D) and at
8 Rt = 5 min (E)
9 **Figure 3.** Biotransformation of furosemide by *A. candidus*. LC-MS ion-current chromatogram of m/z 329 in
10 negative mode (A), of m/z 329 in positive mode (B) and of m/z 249 in negative mode (C) and masse spectra of
11 peak at Rt = 6 min (D) and at Rt = 1.1 min (E)
12 **Figure 4.** Time course in biotransformation of furosemide by *C. echunilata* ATCC 9245 (A and B) and *A.*
13 *candidus* ATCC 20023 (C and D) in different buffers: citrate pH 5 (A and C), phosphate pH 7 (B and D). FRSM
14 (■), HK (▲), SLMN (◆), pH buffer citrate (--▷--), pH buffer phosphate (--○--).
15 **Figure 5.** Evolution of PRDN metabolite during FRSM biotransformation by *C. echunilata* ATCC 9245 (A) and
16 *A. candidus* ATCC 20023 (B). PRDN buffer citrate (▶), PRDN buffer phosphate (●), pH buffer citrate (--▷--)
17 and pH buffer phosphate (--○--).
18 **Figure 6.** EC20 (■) and EC50 (■) toxicity values (mg L⁻¹) for *V. fischeri* luminiscence acute tests with 95%
19 confidence limits. NE = No Effect.
20 **Figure 7.** Inhibition percentage curves for FRSM (■) and the prepared metabolites, PRDN (×) and HK (▲),
21 fitted to nonlinear regression with variable Hill slope.

22
23